Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial

被引：0

作者：

Junichi Koike

Kimihiko Funahashi

Kazuhiko Yoshimatsu

Hajime Yokomizo

Hayato Kan

Takeshi Yamada

Hideyuki Ishida

Keiichiro Ishibashi

Yoshihisa Saida

Toshiyuki Enomoto

Kenji Katsumata

Masayuki Hisada

Hirotoshi Hasegawa

Keiji Koda

Takumi Ochiai

Kazuhiro Sakamoto

Hiroyuki Shiokawa

Shimpei Ogawa

Michio Itabashi

Shingo Kameoka

机构：

[1] Toho University School of Medicine,Department of Gastroenterological Surgery, Omori Medical Center

[2] Tokyo Women’s Medical University Medical Center East,Department of Surgery

[3] Nippon Medical School,Department of Gastrointestinal and Hepato

[4] Saitama Medical University,Biliary

[5] Toho University Ohashi Medical Center,Pancreatic Surgery

[6] Tokyo Medical University,Department of Digestive Tract and General Surgery, Saitama Medical Center

[7] Keio University School of Medicine,Department of Surgery

[8] Teikyo University Chiba Medical Center,Department of Digestive Surgery and Pediatric Surgery

[9] Tokyo Metropolitan Health and Medical Treatment Corporation,Department of Surgery

[10] Juntendo University,Department of Surgery

[11] Tokyo Women’s Medical University,Department of Surgery, Tobu Chiiki Hospital

[12] FACT Trial Group,Department of Coloproctological Surgery, Faculty of Medicine

来源：

Cancer Chemotherapy and Pharmacology | 2017年 / 79卷

关键词：

mFOLFOX6; Rectal cancer; Resectable; Neoadjuvant chemotherapy; Preoperative chemotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：519 / 525

页数：6

共 87 条

[21]

Nowacki MP(2009)Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial J Clin Oncol 27 3109-237

[22]

Nasierowska-Guttmejer A(2004)FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 51 229-674

[23]

Michalski W(2002)Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients Int J Radiat Oncol Biol Phys 53 664-160

[24]

Bebenek M(1999)Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer Radiother Oncol 51 153-2772

[25]

Kryj M(2007)Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? Ann Surg Oncol 14 2766-835

[26]

Latkauskas T(2016)Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study Eur J Surg Oncol 42 829-264

[27]

Pauzas H(2005)Unfavourable expression of pharmacologic markers in mucinous colorectal cancer Br J Cancer 92 259-875

[28]

Gineikiene I(2011)DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy J Natl Cancer Inst 103 863-257

[29]

Gérard JP(2003)Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer N Eng J Med 349 247-undefined

[30]

Conroy T(undefined)undefined undefined undefined undefined-undefined

← 1 2 3 4 5 6 7 8 9 →